• Citer

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.

par Rice, Todd W;Wheeler, Arthur;Bernard, Gordon;Vincent, Jean Louis ;Angus, Derek;Aikawa, Naoki;Demeyer, Ignace;Sainati, Stephen;Amlot, Nicholas;Cao, Charlie;Ii, Masayuki;Matsuda, Hideyasu;Mouri, Kouji;Cohen, Jonathan
Référence Critical care medicine, 38, 8, page (1685-1694)
Publication Publié, 2010-08

Article révisé par les pairs

• Détails
• Contenu

Résumé :

To evaluate whether TAK-242, a small-molecule inhibitor of Toll-like receptor-4-mediated signaling, suppresses cytokine levels and improves 28-day all-cause mortality rates in patients with severe sepsis.